Post by Medical Device Network

Dexcom has reported Q1 revenues of around $1.2bn, indicative of a 15% rise year-over-year (YoY), but will maintain its prior 2026 revenue outlook. Dexcom expects 2026 revenue to fall in the $5.16bn to $5.25bn range, representing growth of between 11%-13%. The continuous glucose monitoring (CGM) specialist is also maintaining its gross profit margin outlook of approximately 63%-64%. Dexcom released its Q1 financials after markets closed on 30 April. Correct as at 4:40am EDT, the company’s shares on the Nasdaq stock exchange were down by around 0.7% at $59.15 in pre-market trading, versus $59.55 previously. #CGM #medtechQ1 #diabetescare Read the full report below: https://lnkd.in/es4iRXia